This content is for Raper Capital Pro subscribers only.
To gain access, please subscribe HERE.
This content is for Raper Capital Pro subscribers only.
To gain access, please subscribe HERE.
(Please note: going forward, titles and the introductory paragraph to new idea write-ups will not include the name of the given company being analyzed for 3-4 weeks post publication. This is to further protect and enhance the value of the idea discovery being offered to subscribers) What if I told you there was a small … Continue reading Endor: 100% revenue growth and explosive long-term trajectory at only 7x EBIT and 10x P/E – this German small-cap should triple (and keep going)
A month ago I broke down the Nio/Hefei transaction that purported to put a high valuation on Nio's China business, suggesting that US investors and bondholders were probably being fleeced. With the release of Nio's 20-F annual filing, we can now definitively conclude that the Hefei 'Strategic Transaction' is nothing more than an asset strip, … Continue reading More on NIO: the devil is in the details
This content is for Raper Capital Pro subscribers only.
To gain access, please subscribe HERE.
This content is for Raper Capital Pro subscribers only.
To gain access, please subscribe HERE.
This content is for Raper Capital Pro subscribers only.
To gain access, please subscribe HERE.
Thesis summary: Metlifecare (MET), a New Zealand-listed retirement village operator, is a highly attractive, 'heads I win big, tails I don't lose' type of investment. EQT, the Swedish private equity powerhouse, is attempting to reneg on a recently-agreed takeover of MET at $7/share - a 68% premium to the current quote ($4.16) - by claiming the onset … Continue reading Metlifecare: heads I win big, tails I don’t lose (or better)